The present application relates to methods and compositions for detecting thyroid cancer in mammals, in particular in humans. The invention provides novel bio markers which, in combination, allow effective, specific and sensitive detection of thyroid cancer, particularly to assist in the diagnosis of thyroid lesions in human subjects. The invention further relates to tools and/or kits (such as reagents, probes, primers, chips or arrays) suitable for implementing said methods, and the preparation and uses thereof.
The present invention relates to novel thiazolo[5,4-f]quinazoline compounds and methods that are useful in the amelioration, treatment or control of Down's syndrome or early Alzheimer's disease or in the amelioration, treatment or control of cancers, especially solid tumors. More specifically, the invention relates to DYRK1A and/or DYRK1B inhibitors and to methods for preparing such compounds.
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
C07C 271/28 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
C07D 277/68 - Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
C07C 219/04 - Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
C07D 277/64 - Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
The present invention relates to novel thiazolo[5,4-ƒ]quinazoline compounds and methods that are useful in the amelioration, treatment or control of Down's syndrome or early Alzheimer's disease or in the amelioration, treatment or control of cancers, especially solid tumors. More specifically, the invention relates to DYRK1A and/or DYRK1B inhibitors and to methods for preparing such compounds.
C07D 277/68 - Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
C07C 255/58 - Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
C07C 255/60 - Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Biological reagents (tests) fir checking immunity in relation to tetanus; biological reagents (tests) for diagnosing an infection caused by tetanus; biological or chemical reagents (immunochromatographic tests), for medical use, for detecting anti-tetanus antibodies; pharmaceutical preparations, namely medical diagnostic preparations for use by doctors or medical laboratories; vaccines; medicines for human purposes; bacteriological preparations for medical, biological preparations for medical use, media for bacteriological cultures, chemical preparations for medical use, chemical preparations for pharmaceutical use, cultures of micro-organisms for medical use, preparations of micro-organisms for medical use; aseptic cotton, antiseptic cotton, cotton wool for medical use, absorbent cotton for medical use, absorbent cotton wool for medical use, compresses, surgical dressings, materials for dressings, gauze for dressings, adhesive tape for medical purposes, sticking plasters, tissues impregnated with pharmaceutical lotions, lotions for pharmaceutical use, haemostatic pencils; sterilising preparations, medicinal alcohol, anaesthetics, antiseptics. Surgical and medical apparatus and instruments; syringes for medical use, needles for medical use; testing apparatus for medical purposes, blood testing apparatus; droppers for medical use, hematimeters, injectors for medical use, syringes for injections, enemas for medical use, pumps for medical use, sprays for medical use, vaporisers for medical use, receptacles for applying medicines; cases fitted for medical instruments, doctor's cases. Chemical research, biological research, bacteriological research; chemical analysis; chemistry services. Medical care services, hospitals, health care services, blood bank services; hygienic care for human beings, namely: care for the purposes of cleaning and disinfecting wounds and injuries; Medical services; pharmacy advice; Nursing homes.
The present invention relates to thiazolo[5,4-f]quinazoline compounds of formula (I), methods for preparing such compounds, and the use of these compounds in the amelioration, treatment or control of Down's syndrome or early Alzheimer's disease or in the amelioration, treatment or control of cancers, especially solid tumors. More specifically, the compounds of the invention are useful as DYRK1A and/or DYRK1B inhibitors. (see formula I)
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07C 255/58 - Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
C07D 277/68 - Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
